1. Application of Biosimilars in RA IN Clinical Practice: Key Issues and Challenges  

3. Introduction

4. Differences Between Generics and Biosimilars

5. Clinical Development Program: Biosimilars

6. Differences Between Development of New Generics and New Biosimilar Medications

7. Clinical Trials of Biosimilars

8. EMA Principles for Establishing Biosimilarity

9. Postmarketing Pharmacovigilance for Biosimilars

10. Immune Reactions to Biologic Therapeutics

11. Considerations in Determining Immunogenicity

12. Extrapolation to Other Indications

13. Clinical Study of Rituximab Biosimilar Candidate CT-P10 Performed in RA

14. Biosimilar Naming and Traceability

15. FDA Proposal on Biosimilar Nomenclature

16. Redefining "Switching"

17. Patient Case 1

18. Patient Case 1: A Clinician’s Perspective

19. Cost: Clinician’s Perspective

20. Starting a Patient on a Biosimilar: Another Clinician’s Perspective

21. Patient Case 2

22. Patient and Physician Considerations in a Nonmedical Switch

23. Physician Considerations: Nonmedical Switch

24. DANBIO Registry: Effect of Nonmedical Switch From Originator to Biosimilar Infliximab

25. Adherence Results for the DANBIO Registry After a Nonmedical Switch

26. Importance of Doctor-Patient Communication

27. Switching Between Multiple Biosimilars?

28. Patient Case 3

29. Adherence in RA: Generally Low for Conventional Treatments

30. Encouraging Adherence and Informing the Patient

31. Acceptance of Biosimilars

32. Concluding Remarks

33. Abbreviations